Payment overview · 2025
General Payments
$866.97
25 reported records · 16 companies
Healthcare provider profile · identity verified
Bertrand M Anz, M.D.
Allopathic & Osteopathic Physicians|General Practice · CHATTANOOGA, TN · NPI 1205996014
Verified facts
What the public records show
CMS Open Payments records show Bertrand M Anz, M.D. received $866.97 in general payments during 2025 across 25 reported records.
AstraZeneca Pharmaceuticals LP accounted for 27.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 21 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jakafi, Verzenio.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Xospata as an associated drug or biological on 1329 records involving 827 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Xospata by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CALQUENCE as an associated drug or biological on 8404 records involving 3935 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Calquence by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LYNPARZA as an associated drug or biological on 9531 records involving 5030 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Lynparza by this doctor in 2024.
Celgene Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 25 records involving 24 distinct recipient NPIs. Public Medicare Part D data also shows 167 claims for Eliquis by this doctor in 2024.
Celgene Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported POMALYST as an associated drug or biological on 282 records involving 237 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Pomalyst by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 167 claims for Eliquis by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported KRAZATI as an associated drug or biological on 49 records involving 45 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Krazati by this doctor in 2024.
Incyte Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JAKAFI as an associated drug or biological on 14854 records involving 6477 distinct recipient NPIs. Public Medicare Part D data also shows 99 claims for Jakafi by this doctor in 2024.
Janssen Biotech, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 24 records involving 23 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Xarelto by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VERZENIO as an associated drug or biological on 9278 records involving 4763 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Verzenio by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROMACTA as an associated drug or biological on 47 records involving 47 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Promacta by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $239.05 | 27.6% | 2 | 2025 |
| Kite Pharma, Inc. | Unresolved — no canonical attribution shown | $110.76 | 12.8% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $74.09 | 8.6% | 3 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $74.04 | 8.5% | 3 | 2025 |
| ADC THERAPEUTICS AMERICA, INC. | Unresolved — no canonical attribution shown | $57.49 | 6.6% | 3 | 2025 |
| Incyte Corporation | Unresolved — no canonical attribution shown | $50.73 | 5.8% | 2 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $48.18 | 5.6% | 2 | 2025 |
| Exelixis Inc. | Unresolved — no canonical attribution shown | $28.14 | 3.2% | 1 | 2025 |
| Celgene Corporation | Unresolved — no canonical attribution shown | $27.45 | 3.2% | 1 | 2025 |
| KYOWA KIRIN, INC. | Unresolved — no canonical attribution shown | $25.75 | 3.0% | 1 | 2025 |
| EMD Serono, Inc. | Unresolved — no canonical attribution shown | $24.47 | 2.8% | 1 | 2025 |
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $22.57 | 2.6% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $21.70 | 2.5% | 1 | 2025 |
| TAIHO ONCOLOGY, INC. | Unresolved — no canonical attribution shown | $21.32 | 2.5% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $21.06 | 2.4% | 1 | 2025 |
| Genmab U.S., Inc. | Unresolved — no canonical attribution shown | $20.17 | 2.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $866.97 | 25 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Yescarta Normalized: yescarta |
Drug | Kite Pharma, Inc. | $110.76 | 1 | 2025 |
Source payment records
|
|||||
| Trodelvy Normalized: trodelvy |
Drug | Gilead Sciences, Inc. | $74.04 | 3 | 2025 |
Source payment records
|
|||||
| ZYNLONTA Normalized: zynlonta |
Drug | ADC THERAPEUTICS AMERICA, INC. | $57.49 | 3 | 2025 |
Source payment records
|
|||||
| Vyloy Normalized: vyloy |
Drug | Astellas Pharma US Inc | $48.18 | 2 | 2025 |
Source payment records
|
|||||
| Fabhalta Normalized: fabhalta |
Drug | Novartis Pharmaceuticals Corporation | $41.17 | 2 | 2025 |
Source payment records
|
|||||
| KISQALI Normalized: kisqali |
Drug | Novartis Pharmaceuticals Corporation | $32.92 | 1 | 2025 |
Source payment records
|
|||||
| CABOMETYX Normalized: cabometyx |
Drug | Exelixis Inc. | $28.14 | 1 | 2025 |
Source payment records
|
|||||
| REBLOZYL Normalized: reblozyl |
Biological | Celgene Corporation | $27.45 | 1 | 2025 |
Source payment records
|
|||||
| POTELIGEO Normalized: poteligeo |
Drug | KYOWA KIRIN, INC. | $25.75 | 1 | 2025 |
Source payment records
|
|||||
| JAKAFI Normalized: jakafi |
Drug | Incyte Corporation | $25.59 | 1 | 2025 |
Source payment records
|
|||||
| MONJUVI Normalized: monjuvi |
Drug | Incyte Corporation | $25.14 | 1 | 2025 |
Source payment records
|
|||||
| PEMAZYRE Normalized: pemazyre |
Drug | Incyte Corporation | $25.14 | 1 | 2025 |
Source payment records
|
|||||
| RYBREVANT Normalized: rybrevant |
Drug | Janssen Biotech, Inc. | $22.57 | 1 | 2025 |
Source payment records
|
|||||
| JAYPIRCA Normalized: jaypirca |
Drug | Lilly USA, LLC | $21.70 | 1 | 2025 |
Source payment records
|
|||||
| RETEVMO Normalized: retevmo |
Drug | Lilly USA, LLC | $21.70 | 1 | 2025 |
Source payment records
|
|||||
| VERZENIO Normalized: verzenio |
Drug | Lilly USA, LLC | $21.70 | 1 | 2025 |
Source payment records
|
|||||
| INQOVI Normalized: inqovi |
Drug | TAIHO ONCOLOGY, INC. | $21.32 | 1 | 2025 |
Source payment records
|
|||||
| LONSURF Normalized: lonsurf |
Drug | TAIHO ONCOLOGY, INC. | $21.32 | 1 | 2025 |
Source payment records
|
|||||
| OPDIVO Normalized: opdivo |
Biological | E.R. Squibb & Sons, L.L.C. | $21.06 | 1 | 2025 |
Source payment records
|
|||||
| Epkinly Normalized: epkinly |
Drug | Genmab U.S., Inc. | $20.17 | 1 | 2025 |
Source payment records
|
|||||
| TAGRISSO Normalized: tagrisso |
Drug | AstraZeneca Pharmaceuticals LP | $14.98 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JAKAFI jakafi |
2025 | Jakafi | 2024 | 99 | exact normalized | Medicare Part D |
| VERZENIO verzenio |
2025 | Verzenio | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Xospata open payments reported associated product |
CMS Open Payments — General Payments 1329 supporting records · 827 recipient NPIs · example record 1238560680 |
Xospata · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | CALQUENCE open payments reported associated product |
CMS Open Payments — General Payments 8404 supporting records · 3935 recipient NPIs · example record 1206131382 |
Calquence · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | LYNPARZA open payments reported associated product |
CMS Open Payments — General Payments 9531 supporting records · 5030 recipient NPIs · example record 1206131376 |
Lynparza · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Celgene Corporation Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 25 supporting records · 24 recipient NPIs · example record 1184385048 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
167 | 43 |
| Celgene Corporation Exact reporting entity; no affiliate inference |
2025 | POMALYST open payments reported associated product |
CMS Open Payments — General Payments 282 supporting records · 237 recipient NPIs · example record 1184378437 |
Pomalyst · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
167 | 43 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | KRAZATI open payments reported associated product |
CMS Open Payments — General Payments 49 supporting records · 45 recipient NPIs · example record 1184404422 |
Krazati · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Incyte Corporation Exact reporting entity; no affiliate inference |
2025 | JAKAFI open payments reported associated product |
CMS Open Payments — General Payments 14854 supporting records · 6477 recipient NPIs · example record 1225959940 |
Jakafi · 2024 Exact normalized brand match · 1 Part D row |
99 | 12 |
| Janssen Biotech, Inc. Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 24 supporting records · 23 recipient NPIs · example record 1174259978 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | VERZENIO open payments reported associated product |
CMS Open Payments — General Payments 9278 supporting records · 4763 recipient NPIs · example record 1186464449 |
Verzenio · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | PROMACTA open payments reported associated product |
CMS Open Payments — General Payments 47 supporting records · 47 recipient NPIs · example record 1200028032 |
Promacta · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Prednisone | Prednisone | 204 | 63 |
| Acyclovir | Acyclovir | 200 | 52 |
| Eliquis | Apixaban | 167 | 43 |
| Ondansetron Odt | Ondansetron | 156 | 77 |
| Abiraterone Acetate | Abiraterone Acetate | 111 | 19 |
| Revlimid | Lenalidomide | 105 | 16 |
| Jakafi | Ruxolitinib Phosphate | 99 | 12 |
| Venclexta | Venetoclax | 93 | 20 |
| Anastrozole | Anastrozole | 86 | 31 |
| Dexamethasone | Dexamethasone | 83 | 33 |
| Brukinsa | Zanubrutinib | 73 | 12 |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 69 | 51 |
| Folic Acid | Folic Acid | 55 | 16 |
| Levothyroxine Sodium | Levothyroxine Sodium | 47 | 13 |
| Potassium Chloride | Potassium Chloride | 47 | 21 |
| Hydrocortisone | Hydrocortisone | 46 | 11 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 45 | 21 |
| Ondansetron Hcl | Ondansetron Hcl | 42 | 15 |
| Ninlaro | Ixazomib Citrate | 40 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 38 | 25 |
| Voriconazole | Voriconazole | 36 | suppressed |
| Promacta | Eltrombopag Olamine | 35 | suppressed |
| Fluconazole | Fluconazole | 33 | 17 |
| Hydroxyurea | Hydroxyurea | 33 | 15 |
| Levofloxacin | Levofloxacin | 33 | 24 |
| Neulasta Onpro | Pegfilgrastim | 32 | 13 |
| Promethazine Hcl | Promethazine Hcl | 31 | 14 |
| Xarelto | Rivaroxaban | 30 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 24 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 23 | suppressed |
| Letrozole | Letrozole | 22 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 21 | 12 |
| Ibrance | Palbociclib | 20 | suppressed |
| Tamoxifen Citrate | Tamoxifen Citrate | 20 | suppressed |
| Calquence | Acalabrutinib Maleate | 19 | suppressed |
| Exemestane | Exemestane | 18 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 18 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 17 | 13 |
| Pomalyst | Pomalidomide | 17 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 17 | suppressed |
| Allopurinol | Allopurinol | 16 | suppressed |
| Furosemide | Furosemide | 16 | 12 |
| Lynparza | Olaparib | 16 | suppressed |
| Olanzapine | Olanzapine | 16 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 15 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 15 | suppressed |
| Xospata | Gilteritinib Fumarate | 15 | suppressed |
| Deferasirox | Deferasirox | 14 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 14 | suppressed |
| Imatinib Mesylate | Imatinib Mesylate | 14 | suppressed |
| Lenalidomide | Lenalidomide | 14 | suppressed |
| Metformin Hcl | Metformin Hcl | 14 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 14 | suppressed |
| Gabapentin | Gabapentin | 13 | suppressed |
| Zenpep | Lipase/Protease/Amylase | 13 | suppressed |
| Alprazolam | Alprazolam | 12 | suppressed |
| Bosulif | Bosutinib | 12 | suppressed |
| Everolimus | Everolimus | 12 | suppressed |
| Lidocaine-Prilocaine | Lidocaine/Prilocaine | 12 | suppressed |
| Lumakras | Sotorasib | 12 | suppressed |
| Mirtazapine | Mirtazapine | 12 | suppressed |
| Pyrukynd | Mitapivat Sulfate | 12 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 12 | suppressed |
| Verzenio | Abemaciclib | 12 | suppressed |
| Krazati | Adagrasib | 11 | suppressed |
| Lorbrena | Lorlatinib | 11 | suppressed |
| Lytgobi | Futibatinib | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $866.97 · 25 records | AstraZeneca Pharmaceuticals LP | CABOMETYX, Epkinly, Fabhalta, INQOVI, JAKAFI, JAYPIRCA, KISQALI, LONSURF, MONJUVI, OPDIVO, PEMAZYRE, POTELIGEO, REBLOZYL, RETEVMO, RYBREVANT, TAGRISSO, Trodelvy, VERZENIO, Vyloy, Yescarta, ZYNLONTA | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jakafi play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Astellas Pharma US Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error